Does reduction in immunosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? A prospective study

Transplantation

Volumn 85, Issue 8, 2008, Pages 1099-1104

  Alméras, Cyrielle ^a   Foulongne, Vincent ^a   Garrigue, Valérie ^a   Szwarc, Ilan ^a   Vetromile, Fernando ^a   Segondy, Michel ^a   Mourad, Georges ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

BK virus; BKVN; Immunosuppressive regimen; Renal transplantation

Indexed keywords

BASILIXIMAB; CALCINEURIN; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; BK VIRUS; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; VIREMIA;

ADULT; AGED; BK VIRUS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; TUMOR VIRUS INFECTIONS; VIRAL LOAD; VIREMIA;

EID: 42549130945     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31816a33d4     Document Type: Article

References (26)

1. Stolt A, Sasnauskas K, Koskela P, et al. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003; 84: 1499.
2. Polo C, Perez JL, Mielnichuck A, et al. Prevalence and patterns of polyomavirus urinary excretion in immunocompetent adults and children. Clin Microbiol Infect 2004; 10: 640.
3. Hirsch HH, Knowles W, Dickemann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal transplant recipients. N Engl J Med 2002; 347: 488.
4. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of pre-emptive immunosuppression reduction. Am J Transplant 2005; 5: 582.
5. Vasudev B, Hariharan S, Hussain SA, et al. BK virus infection: Risk factors, timing, and outcome in renal transplant recipients. Kidney Int 2005; 68: 1834.
6. Ramos E, Drachenberg CB, Papadimitriou JC, et al. Clinical course of polyomavirus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13: 2145.
7. Wadei HM, Rule AD, Lewin M, et al. Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus associated nephropathy (PVAN). Am J Transplant 2006; 6: 1025.
8. Drachenberg CB, Papadimitriou JC, Wali R, et al. Improved outcome of polyoma virus allograft nephropathy with early biopsy. Transplant Proc 2004; 36: 758.
9. Hariharan S. BK virus nephritis after renal transplantation. Kidney Int 2006; 69: 655.
10. Nickeleit V, Klimkait T, Binet I, et al. Testing for polyomavirus type BK DNAin plasma to identify renal allograft recipients with viral nephropathy. N Engl J Med 2000; 342: 1309.
11. Drachenberg CB, Hirsch HH, Ramos E, et al. Polyomavirus disease in renal transplantation review of pathological findings and diagnostic methods. Hum Pathol 2005; 36: 1245.
12. Nickeleit V, Hirsch HH, Binet IF, et al. Polyomavirus infection of renal allograft recipients: From latent to manifest disease. J Am Soc Nephrol 1999; 10: 1080.
13. Drachenberg CB, Papadimitriou JC, Hirsch HH, et al. Histological patterns of polyomavirus nephropathy: Correlation with graft outcome and viral load. Am J Transplant 2004; 4: 2082.
14. Hirsch HH, Brennan D, Drachenberg C, et al. Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 2005; 79: 1277.
15. Mourad G, Rostaing L, Legendre C, et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004; 78: 584.
16. Djamali A, Turc-Baron C, Portales P, et al. Low dose antithymocytes globulins in renal transplantation: Daily versus intermittent administration based on T cell monitoring. Transplantation 2000; 69: 799.
17. Whiley DM, Mackey IM, Sloots TP. Detection and differentiation of human polyomaviruses JC and BK by LightCycler PCR. J Clin Microbiol 2001; 39: 4357.
18. Drachenberg CB, Beskow CO, Cangro CB, et al. Human polyoma virus in renal allograft biopsies: Morphological findings and correlation with urine cytology. Hum Pathol 1999; 30: 970.
19. Racusen LC, Solez K, Colvin RB, et al The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
20. Hymes LC, Warshaw BL. Polyomavirus (BK) in paediatric renal transplant: Evaluation of viremic patients with and without BK associated nephritis. Pediatr Transplant 2006; 10: 920.
21. Buehrig CK, Lager DJ, Stegall MD, et al. Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney Int 2003; 64: 665.
22. Rocha PN, Plumb TJ, Miller SE, et al. Risk factors for BK polyomavirus nephritis in renal allograft recipients. Clin Transplant 2004; 18: 456.
23. Kadambi PV, Josephson MA, Williams J, et al. Treatment of refractory BK virus associated nephropathy with Cidofovir. Am J transplant 2003; 3: 186.
24. Josephson MA, Gillen D, Javaid B, et al. Treatment of renal allograft polyoma BK virus infection with Leflunumide. Transplantation 2006; 81: 704.
25. Kim CK, Song JH, Kim SM, et al. Clinical usefulness of human cytomegalovirus antigenemia assay after kidney transplantation. Transplantation 2003; 75: 2151.
26. Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis 2003; 3: 611.